THERAPY DOSSIER · th-131ebd5cad1e

Anti-TNF-alpha monoclonal antibody conjugated to high molecular weight hyaluronic acid

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Burn
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 23765644 ↗2013Mixed findings

Effects of hyaluronic acid conjugation on anti-TNF-alpha inhibition of inflammation in burns.

RatBurnContact / flameSprague-Dawleyn = 16 rats, 4 per groupTopical to the debrided burn wound under Tegaderm dressing200 microL per application of 5% hyaluronic acid conjugate…First treatment on day 0, the day after burn, immediately after eschar excision

Model: Deep partial-thickness contact burn made with a 17 mm brass disc weighted with 500 g and heated to 85 degrees C applied to shaved dorsal skin for 10 s, with eschar excision the following day (day 0)

The hyaluronic acid conjugate produced the greatest reduction in non-viable tissue at day 7 (p < 0.003 versus all other treatments) and lowered IL-1beta versus saline at days 4 and 7, whereas non-conjugated antibody reduced macrophage counts most (approximately 75% below saline at days 4 and 7) but…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.

Loading the evidence…